Choroid plexus tumors (CPTs) occur spontaneously in humans and dogs providing an opportunity for comparative cross species analysis of common tumor mechanisms. Large scale chromosomal copy number alterations are the hallmark of human CPTs and identification of driver genes within these regions is problematic. Copy number alterations in 12 spontaneous dog CPTs were defined using an Illumina 170 K single nucleotide polymorphism array and were characterized by highly recurrent whole chromosomal losses in up to 100% of cases with few chromosome wide gains. Loss of canine chromosomes 2, 5, 8, and 20 were seen in 90%-100% of cases and included regions syntenic to loci within commonly reported whole chromosome losses in human choroid plexus tumors. These regions included previously defined tumor suppressor clusters on chromosome 3p and 17p as well as genes associated with chromosomal instability such as TP53 and VHL. This karyotypic signature is similar to a previously defined hypodiploid subgroup of human choroid plexus carcinomas. The nonrandom, highly recurrent alterations in dog CPTs suggest specific selection pressures and oncogenic mechanisms are present. More extensive analysis of this spontaneous tumor model is warranted and may provide key insights into driver mechanisms common to both species.
INTRODUCTION
Choroid plexus tumors (CPTs) constitute 0.3%-0.8% of human brain tumors, although they account for up to 4% of tumors in children <15 years, and up to 20% of tumors occurring in the first year of life (1) (2) (3) . Spontaneously arising CPTs represent approximately 6% of brain tumors in dogs (4) with histological and imaging characteristics essentially indistinguishable from their human tumor counterparts ( Fig. 1) , although the median age of affected animals is approximately 6 years and juvenile tumors are rare (5) (6) (7) . WHO grades I (papilloma [CPP] ), II (atypical papilloma [aCPP] ) and III (carcinoma [CPC] ) are seen in humans and dogs; while approximately 60% of human CPTs are CPPs (1), a majority of dog CPTs in larger reported studies are either atypical or more commonly grade III carcinomas (5, (7) (8) (9) .
Cytogenetic studies of human CPTs have revealed a high degree of chromosomal instability in a majority of tumors (reviewed in Merino et al [10] ) frequently associated with whole chromosomal losses and gains (10) (11) (12) (13) (14) . These chromosomal scale copy number alterations (CNAs) are common in cancer (15) , particularly in pediatric tumors and identifying driver genes within these large alterations is challenging. Cross-species studies using induced mouse tumor models have been used to gain insight into this dilemma, and have identified syntenic chromosomal alterations in a variety of tumors including choroid plexus carcinoma (16) . Conservation of CNAs between humans and dogs has also been demonstrated in a variety of spontaneous, naturally occurring tumor types, suggesting common underlying etiologies (17, 18) . Given the similar biology of CPTs in humans and dogs, we sought to define if similar whole chromosome alterations found in human CPTs were present in naturally occurring dog CPTs and whether syntenic regions of alteration would highlight common candidate genes for further study.
MATERIALS AND METHODS

Samples
Primary tumor tissue was obtained at necropsy or from surgical biopsy of clinical cases presented to the University of California, Davis Veterinary Medical Teaching Hospital. Necropsy samples were collected within 30 minutes of death.
All samples were snap-frozen in liquid nitrogen for storage. Samples of adjacent tumor tissue were paraffin-embedded and processed for histological analysis. All tumors were histologically classified by a board-certified pathologist according to the WHO classification of human tumors of the central nervous system (19) . Control tissues consisted of either white blood cells collected from EDTA blood sample buffy coats, normal liver or muscle. Genomic DNA was extracted from all samples using Qiagen kits (Qiagen, Valencia, CA).
Single Nucleotide Polymorphism Analysis
Genome-wide single nucleotide polymorphism (SNP) genotyping was performed on 11 paired samples (tumor and nontumor) as well as 1 recurrent choroid plexus papilloma using the Illumina CanineHD BeadChip with 173, 662 markers. CNAs were called using CNVPartition v 3.2.0 (Illumina) algorithm implemented in Genome studio software. SNPs with a quality score of 0 and intensity only SNPs were removed from subsequent analysis. A minimum probe count of 3 was used and a minimum homozygous region of 1 Mb. GC correction was performed later using Nexus software.
Nexus Copy Number v. 7.5.2 (Biodiscovery, Hawthorne, CA) was used to determine structural variation in the paired samples. The SNP-FASST2 segmentation Algorithm was used to estimate the final copy number and allelic event calls. The significance threshold for segmentation was set at 1 Â 10 À9 also requiring a minimum of 3 probes per segment and a maximum probe spacing of 1 Mb between adjacent probes before breaking a segment.
The log ratio thresholds for single copy gain and single copy loss were set at 0.1 and À0.15, respectively. The log ratio thresholds for 2 or more copy gains and homozygous losses were set at 0.41 and À1.1, respectively. The homozygous frequency threshold was set to 0.85. The homozygous value threshold was set to 0.8. The Heterozygous imbalance threshold was set to 0.4. The minimum loss of heterozygosity length was set at 500 Kb and minimum SNP probe density at 3. Probes were manually centered to the median using diploid samples. Systematic GC wave correction was applied using a linear correction. Data were aligned to CanFam3.1 (20) .
Cluster Analysis
Clustering analysis of aberration profiles was done using an average linkage hierarchical clustering algorithm.
Comparisons
Chromosomal regions reported as being significantly different in terms of frequency of an aberration in group A versus group B met a minimum p value of <0.05 based on a 2-tailed Fisher Exact test as well as a minimum of 25% difference in frequencies between the 2 groups. Analysis of regions with constant frequency and "combined" analysis was done by merging all contiguous regions that met the p value threshold.
Frequency Significance Testing
Testing was done using 2 algorithms: (i) STAC: Areas of the genome with a statistically high frequency of aberration (p < 0.05) and an aggregate cut-off of 25% were identified using the global frequency statistic approach of the STAC (Significance Testing for Aberrant Copy number) method (21) .
(ii) GSTIC: Areas of the genome with a statistically high frequency of aberration (Q-bound value <0.05 and G-score cutoff >1.0) corrected for multiple testing using FDR correction (22) were identified using the GISTIC (Genomic Identification of Significant Targets in Cancer) approach (23) . G score is a measure of both frequency of occurrence and the magnitude of the copy number change. Regions were reported as both peak regions and extended regions that defined the widest boundaries repeatedly recalculated by leaving out 1 of the samples each time.
Tumor Suppressor Gene Assessment
The syntenic regions between Human (Homo sapiens, GRCh38) and Dog (Canis lupus familiaris, CanFam3.1) were extracted from their pairwise alignment in Ensembl release 76. Candidate tumor suppressor genes were extracted from the TSGene Tumor Suppressor Gene Database knowledgebase (24) , and dog homologues identified using Ensembl Biomart with manual correction (25) . Candidate chromosomal instability genes were taken from Thompson et al (26) and dog homologs annotated manually using Ensembl.
RESULTS
Details of samples are presented in the Table. Samples consisted of 4 CPPs (grade I) including 1 recurrent tumor and 8 CPCs (grade III). Copy number alterations were characterized by high frequency loss of specific whole chromosomes across all samples (Fig. 2) . Copy number gains were infrequent and generally restricted to specific gains in isolated tumors. There were no homozygous copy number losses or high copy number gains. Recurrent whole chromosome losses present in 50% or more of samples were seen involving 6 chromosomes. Loss of dog chromosome 2 (Canis Hierarchical clustering analysis did not distinguish between CPP and CPC or between tumor location (Fig. 3) . Significant differences between tumor subtypes based on comparative analysis of aberration profiles was restricted to CFA4 losses in CPP. Losses seen exclusively in CPC (>30% samples) consisted of whole chromosomal losses of CFA21, 25 and 26; however, these were not statistically significant (Fig. 3) .
High frequency losses of tumor suppressor genes and genes associated with chromosomal instability are listed in Supplementary Data Digital Content S2. Of note, loss of chromosomal instability associated genes TP53, VHL, CENPH, KIF2A, HAUS8 and AURKB was seen in over 90% of tumors.
Whole chromosome losses involving CFA2, 5, 20, and 33 were syntenic with regions of commonly deleted whole chromosomes in CPTs including loss of human chromosome 3 (Homo SApiens/HSA 3), 5, 11, 16, and 17 ( Fig. 4 ; Supplementary Data Digital Content S1).
DISCUSSION
Cytogenetic analysis of human CPTs consistently demonstrates a high degree of genomic instability and large chromosomal scale CNAs. These data together with mutational and epigenetic studies have revealed several clinically relevant subgroups (10, 11, 13) , suggesting that a variety of oncogenic mechanisms may be responsible for specific tumor populations. Given the uniformity of the karyotypic changes in dog CPTs it is possible that they may be comparable to a specific subgroup of human CPTs. Canine CPTs (CPPs and CPCs) are characterized by a strikingly consistent loss of specific whole chromosomes that is most comparable to human CPCs based on previous studies (10) (11) (12) (13) (14) .
Significance of specific chromosomal percentage losses in human CPTs compared to dog CPTs is somewhat difficult to define due to pooling of subgroup data from human CPP, aCPP, and CPC in most reports; however, many of the most consistently reported losses (e.g. HSA 3, 5, 6, 11, 16, 22) (10-14, 27) have syntenic correlates in dog CPTs. The larger number of small autosomal chromosomes in the dog karyotype compared to humans (38 vs 22) means that mapping these high frequency dog chromosomal losses onto syntenic human regions may provide a mechanism to identify key regions within human whole chromosomal alterations, if karyotypic mechanisms are conserved across species (17, 18, 28, 29) . Losses occurring in >50% of dog CPTs included CFA 2, 5, 8, 19, 20, 31 , and 33, and syntenic regions in human chromosomes ( Fig. 4 ; Supplementary Data Digital Content S1) include regions within some of the most commonly reported chromosomal losses in human CPCs, specifically HSA 3, 5, 11, 16, and 17. Not all common chromosomal losses in human CPTs (e.g. HSA 6 and 22) were represented in the canine tumors, possibly reflecting the numerous subgroups previously defined in human tumors and the apparent homogeneity of the karyotypic changes in dog CPTs. Within the human CPC group, subgroups have been associated with a more consistent hypodiploid phenotype, specifically in younger patients (11), and Merino et al described a subgroup of hypodiploid CPCs characterized by a very low frequency of associated copy number gains, bearing strong similarities to the karyotypic signature of canine CPTs (10) . Interestingly, this hypodiploid group was characterized by loss of HSA3 in all cases, which mirrors the 100% loss of CFA20 syntenic to regions of HSA3. Loss of HSA11 and 16 in these hypodiploid CPCs (80% cases) was also mirrored by syntenic loss of CFA5 in 92% of dog CPTs (10) . Similar CPC subgroups characterized by either predominantly hyper or hypo-diploid signatures have been reported by Ruland et al (11) and Japp et al (12) who also described CPCs with extensive chromosomal losses (most commonly HSA3) and minimal copy number gains.
Within the regions of syntenically conserved deletions, numerous tumor suppressor genes and genes associated with chromosomal stability were identified as potential candidates for further study as key drivers common to both species. Defining the driver genes within these high frequency syntenic regions will be facilitated by more extensive mutational, transcriptional and epigenetic characterization of the dog tumors. Downregulated genes that have been previously associated with chromosomal instability and were deleted in 90%-100% of tumors (KIF2A, HAUS8, VHL, AURKB, and TP53) are specific targets for further assessment. A previous report investigating concordance of copy number loss and tumor suppressor gene expression in a variety of human cancer types identified 3 potentially important genomic regions including 3p21 and 17p13. 1-3 (30) . Both these syntenic regions were deleted in 90%-100% dog tumors (CFA 20, 5) and incorporate a high density of tumor suppressor genes including TP53 (Fig. 4) . Given its pivotal roles in both oncogenesis and maintenance of genomic integrity, the high frequency loss of TP53 gene copies is interesting. Compared to genomic deletions, TP53 mutations are uncommon in human CPPs but present in 35%-60% of CPCs, both in sporadically occurring CPTs (10, 12, 14) , and in patients with germ line mutations of the TP53 gene (Li-Fraumeni syndrome) (10, 14, 27, 31, 32) . CPCs in humans with TP53 mutations have been shown to have higher structural variation including chromosomal losses associated with higher genomic instability and poorer prognosis (10, 14, 33) . A role for altered TP53 pathway function in dog CPT oncogenesis and genomic instability is possible given the high frequency of CFA 5 loss. Available data suggests that TP53 mutations are uncommon in dog CPTs compared to humans (34); however, additional TP53 perturbation may occur through many alternate mechanisms as has been shown previously when comparing dog and human tumor correlates (17) , and haploinsufficiency may be a sufficient driver of tumorigenesis as is the case for many tumor suppressor genes including TP53 (35, 36) .
In addition to familial germ line mutations of TP53, CPTs have also been associated less commonly with another familial disorder, von Hippel-Lindau disease with loss of VHL gene function (HSA3) (37) . Haploinsufficiency of VHL was present in all dog tumors associated with loss of CFA20.
Molecular-genetically defined subgroups of tumors within the general and subtype specific classification of CPTs are being more extensively defined and are likely to have important implications for prognosis and future development of targeted therapeutic strategies. A majority of human CPCs occur in younger children (1, 3, 11, 13) , and a subgroup of hypodiploid tumors with minimal chromosomal amplifications has been identified in several studies. The similar high frequency syntenic chromosomal deletions in dog CPTs follow a nonrandom pattern and suggest they are under selection and are likely to be drivers rather than passengers. These canine tumors may represent a useful translational model with the potential to provide both mechanistic and therapeutic insight into a specific subset of human CPTs.
